These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36147313)

  • 21. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
    Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
    BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.
    Huang S; Zhang J; Lai X; Zhuang L; Wu J
    Front Mol Biosci; 2021; 8():781307. PubMed ID: 35004851
    [No Abstract]   [Full Text] [Related]  

  • 23. Pyroptosis related genes signature predicts prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.
    Fang G; Zhang Q; Fan J; Li H; Ding Z; Fu J; Wu Y; Zeng Y; Liu J
    BMC Cancer; 2022 Sep; 22(1):999. PubMed ID: 36127654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic characterization of alternative splicing related to prognosis, immune infiltration, and drug sensitivity analysis in ovarian cancer.
    Liu Q; Zhang H; Yang X; Liu X; Yin F; Guo P; Yin Y; Zheng K; Yang Z; Han Y
    Ann Transl Med; 2022 Jan; 10(2):126. PubMed ID: 35282039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
    Yan Z; He M; He L; Wei L; Zhang Y
    Front Immunol; 2021; 12():723271. PubMed ID: 34925311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CXCL5/CXCL8 is a promising potential prognostic and tumor microenvironment-related cluster in hepatocellular carcinoma.
    Zhu J; Zhou Y; Wang L; Hao J; Chen R; Liu L; Li J
    J Gastrointest Oncol; 2020 Dec; 11(6):1364-1380. PubMed ID: 33457007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma.
    Zhang D; Duan Y; Cun J; Yang Q
    Front Genet; 2019; 10():278. PubMed ID: 30984247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
    Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
    Front Immunol; 2021; 12():719175. PubMed ID: 34603293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma.
    Wang W; Ye Y; Zhang X; Ye X; Liu C; Bao L
    Front Mol Biosci; 2022; 9():937979. PubMed ID: 35911976
    [No Abstract]   [Full Text] [Related]  

  • 30. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
    Tang P; Qu W; Wang T; Liu M; Wu D; Tan L; Zhou H
    Front Genet; 2021; 12():785185. PubMed ID: 34917132
    [No Abstract]   [Full Text] [Related]  

  • 32. Identification of Prognostic Glycolysis-Related lncRNA Signature in Tumor Immune Microenvironment of Hepatocellular Carcinoma.
    Bai Y; Lin H; Chen J; Wu Y; Yu S
    Front Mol Biosci; 2021; 8():645084. PubMed ID: 33968985
    [No Abstract]   [Full Text] [Related]  

  • 33. Identification of the Tumor Immune Microenvironment and Therapeutic Biomarkers by a Novel Molecular Subtype Based on Aging-Related Genes in Hepatocellular Carcinoma.
    Cai D; Zhao Z; Hu J; Dai X; Zhong G; Gong J; Qi F
    Front Surg; 2022; 9():836080. PubMed ID: 35392063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of a breast cancer prognosis model based on alternative splicing and immune infiltration.
    Zhang D; Lu W; Zhuo Z; Mei H; Wu X; Cui Y
    Discov Oncol; 2022 Aug; 13(1):78. PubMed ID: 35988113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of an Epithelial-Mesenchymal Transition-Related Long Non-coding RNA Prognostic Signature to Determine the Prognosis and Drug Treatment of Hepatocellular Carcinoma Patients.
    Huang S; Li D; Zhuang L; Zhang J; Wu J
    Front Med (Lausanne); 2022; 9():850343. PubMed ID: 35685422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma.
    Xu Q; Xu H; Chen S; Huang W
    Front Cell Dev Biol; 2021; 9():710207. PubMed ID: 34409040
    [No Abstract]   [Full Text] [Related]  

  • 37. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma.
    Li X; Lin J; Pan Y; Cui P; Xia J
    Technol Cancer Res Treat; 2021; 20():15330338211041425. PubMed ID: 34866477
    [No Abstract]   [Full Text] [Related]  

  • 38. Identification and Validation of a Prognostic Immune-Related Alternative Splicing Events Signature for Glioma.
    Wang M; Zhou Z; Zheng J; Xiao W; Zhu J; Zhang C; Jiang X
    Front Oncol; 2021; 11():650153. PubMed ID: 34055619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients.
    Wang Z; Zhang N; Lv J; Ma C; Gu J; Du Y; Qiu Y; Zhang Z; Li M; Jiang Y; Zhao J; Du H; Zhang Z; Lu W; Zhang Y
    Biomed Res Int; 2020; 2020():4037639. PubMed ID: 33163533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
    Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
    BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.